The Potential Role of Biomarkers in Guiding Therapeutic Decisions in MS
Date: - Time: -
Authors: Bruce Cree, MD PhD; Stephen Hauser, MD
This activity is intended for neurologists and multiple sclerosis (MS) specialists.
Data from the medical literature and Medscape Education survey and participant data reveal major knowledge, competency, and performance gaps regarding the importance of early treatment of patients with MS and the role and use of biomarkers. Various biomarkers are being investigated and validated as predictors of disease course and potential response to treatment. Clinicians need to assess these data, understand how biomarkers are related to the mechanisms of action of current and emerging MS therapies, and evaluate the role of biomarkers in the optimal selection and sequencing of therapy. The goal of this activity is to address identified education gaps in learning and competence related to understanding the role and use of biomarkers in predicting treatment efficacy in MS.
Upon completion of this activity, participants will be able to:
1.Evaluate the data on the potential usefulness and limitations of specific biomarkers as guides to therapeutic decision-making in MS, such as which therapy to select and when to initiate, switch, or escalate therapy
2.Identify the unique biomarkers that are related to mechanisms of action of current and emerging therapies and how they may be predictive of treatment response
Credits: Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™